Beyond the well‐known complication of gout and nephroiithiasis, there is a mounting body of evidence that hyperuricemia is associated with hypertension and chronic renal disease and is an independent risk factor for coronary artery disease. It is less clear that treating hyperuricemia leads to better outcomes. Hyperuricemia has been shown in some studies to be associated with the metabolic syndrome. To our knowledge, this association between hyperuricemia and metabolic syndrome has not been confirmed in a Hispanic population. Although gout is rare, nephroiithiasis is relatively common in our population, but far more common are obesity and type 2 diabetes. The purpose of our study was to determine the prevalence of hyperuricemia in an Hispanic population and to assess the association between uric acid level and the components of the metabolic syndrome.
This study was a cross‐sectional study of patients who attended our Continuity Clinic between January and June 2008. Patients between the ages of 20 and 65 years were stratified into 2 groups based on the number of metabolic syndrome components possessed (0–3 components vs. more than 3). Age, sex, BMI, blood sugar, lipid profile, and blood pressure were other variables recorded. Metabolic syndrome was defined by the ATPIII Criteria, whereas hyperuricemia was defined as serum uric acid level > 7 mg/dL in men and > 6 mg/dL in women.
The prevalence of hyperuricemia in our population was 35% (28 of 80 patients). Twelve of 28 men (42.85%) and 16 of 52 women (30.76%) had hyperuricemia. In patients with 0‐3 components of metabolic syndrome, the prevalence was 27%, and in those with more than 3 components it was 45% (P = 0.10). From our power analysis, 200 patients would be required to achieve statistic significance. Though our study was underpowered, it showed a modest positive correlation between hyperuricemia and BMI (r = 0.34, P = 0.002) and between hyperuricemia and systolic blood pressure (r = 0.29, P = 0.009).
Our study showed that more than one third of our patients have hyperuricemia. This became more compelling as the number of metabolic syndrome components increased to 3 or more. Data from recent epidemiologic studies suggests that asymptomatic hyperuricemia in patients with low cardiovascular risk is most likely benign. However, in patients at high cardiovascular risk, hyperuricemia may represent a proinflammatory, ischemic, or oxidative stress burden to the heart and vessels. Therefore, in such patients screening for hyperuricemia may be reasonable, particularly if it is confirmed that lowering uric acid levels helps in controlling hypertension, chronic renal disease, and heart disease.
B. Konwe, UTHSCSA/RAHC, employment; J. Pallapati, Su Clinica Familiar, employment; J. F Hanley, UTHSCA/RAHC, employment.
To cite this abstract:Konwe B, Pallapati J, Hanley J. Hyperuricemia and Its Clinical Correlates in Hispanic Patients with Metabolic Syndrome. Abstract published at Hospital Medicine 2009, May 14-17, Chicago, Ill. Abstract 58. Journal of Hospital Medicine. 2009; 4 (suppl 1). https://www.shmabstracts.com/abstract/hyperuricemia-and-its-clinical-correlates-in-hispanic-patients-with-metabolic-syndrome/. Accessed November 17, 2019.